{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:38:53Z","timestamp":1762144733743},"reference-count":49,"publisher":"Japanese Pharmacological Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2010]]},"DOI":"10.1254\/jphs.10r06fm","type":"journal-article","created":{"date-parts":[[2010,7,27]],"date-time":"2010-07-27T05:20:25Z","timestamp":1280208025000},"page":"310-314","source":"Crossref","is-referenced-by-count":10,"title":["New Approaches to Blockade of the Renin\u2013Angiotensin\u2013Aldosterone System: Mineralocorticoid-Receptor Blockers Exert Antihypertensive and Renoprotective Effects Independently of the Renin\u2013Angiotensin System"],"prefix":"10.1254","volume":"113","author":[{"given":"Akira","family":"Nishiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suwarni","family":"Diah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Hitomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.24.469"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.01.015"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(03)00913-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3:486–492.","DOI":"10.1038\/ncpneph0575"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spiornolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717.","DOI":"10.1056\/NEJM199909023411001"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens. 1995;13:1801–1802.","DOI":"10.1097\/00004872-199512010-00054"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70298-2"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.03.007"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.539122"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01194.x"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.01.007"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000067463.13172.EA"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000044937.95080.E9"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2004.06.029"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.10.040"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200109203451215"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01040905"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033263"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)91030-7"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2009.29"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Gross E, Rothstein M, Dombek S, Juknis HI. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis. 2005;46:94–101.","DOI":"10.1053\/j.ajkd.2005.03.005"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01586-2"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.90903.2008"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02855-3"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens. 2005;18:50–55.","DOI":"10.1016\/j.amjhyper.2004.08.026"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Lane DA, Beevers DG. Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent. J Hypertens. 2007;25:2515–2516.","DOI":"10.1097\/HJH.0b013e3282f254d9"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000182661.98259.4f"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Kobayashi K, Muragaki Y, et al. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension. 2008;51:734–741.","DOI":"10.1161\/HYPERTENSIONAHA.107.104299"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.08R12FM"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.08R02CR"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens. 2006;24:2285–2292.","DOI":"10.1097\/01.hjh.0000249708.44016.5c"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70:2116–2123.","DOI":"10.1038\/sj.ki.5001854"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00240106"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00756.x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536–542.","DOI":"10.1038\/sj.ki.5001580"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.9.2106"},{"key":"38","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.31.59"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.04.020"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000154681.38944.9a"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000255636.11931.a2"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000174593.88899.68"},{"key":"43","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00147.2007"},{"key":"44","unstructured":"44 Kawachi H, Han GD, Miyauchi N, Hashimoto T, Suzuki K, Shimizu F. Therapeutic targets in the podocyte: findings in anti-slit diaphragm antibody-induced nephropathy. J Nephrol. 2009;22:450–456."},{"key":"45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2007.00876.x"},{"key":"46","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000222003.28517.99"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, et al. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther. 2010;332:1072–1080.","DOI":"10.1124\/jpet.109.158113"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370–1376.","DOI":"10.1038\/nm.1879"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283346b62"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T15:08:14Z","timestamp":1621436894000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jphs\/113\/4\/113_10R06FM\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.10r06fm","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010]]}}}